Holen Sie sich die Stockscreener-App
6.01
0.33%
-0.05
Schlusskurs vom Vortag:
$6.06
Offen:
$6.12
24-Stunden-Volumen:
223.02K
Relative Volume:
0.78
Marktkapitalisierung:
$164.29M
Einnahmen:
$47.26M
Nettoeinkommen (Verlust:
$-58.48M
KGV:
-2.2219
EPS:
-2.7049
Netto-Cashflow:
$-40.45M
1W Leistung:
-4.28%
1M Leistung:
-51.64%
6M Leistung:
-40.49%
1J Leistung:
-58.88%
1-Tages-Spanne:
$5.81
$6.183
1-Wochen-Bereich:
$5.81
$6.28
52-Wochen-Spanne:
$5.81
$18.55
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Vergleichen Sie CVRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.02 | 164.29M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
131.48 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
94.77 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
347.45 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.33 | 106.51B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.41 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
CVRx, Inc. (NASDAQ:CVRX) Shares Sold by Alliancebernstein L.P. - Defense World
CVRx, Inc. (NASDAQ:CVRX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CVRx, Inc. (NASDAQ:CVRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
(CVRX) Investment Analysis - news.stocktradersdaily.com
Cantor maintains CVRx stock with $20 target despite revenue miss By Investing.com - Investing.com India
Cantor maintains CVRx stock with $20 target despite revenue miss - Investing.com
William Blair Comments on CVRx’s Q1 Earnings (NASDAQ:CVRX) - Defense World
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles By Investing.com - Investing.com India
CVRx stock slides on preliminary revenue miss - MSN
CVRx, Inc.: Overreaction Creates Buying Opportunity - Seeking Alpha
CVRx Insiders Lose Out As Stock Sinks To US$6.20 - simplywall.st
CVRx’s SWOT analysis: barostim maker’s stock faces growth hurdles By Investing.com - Investing.com India
CVRx's SWOT analysis: barostim maker's stock faces growth hurdles - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating By Investing.com - Investing.com South Africa
CVRx stock touches 52-week low at $6.36 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
CVRx stock drops on Q1 preliminary sales number miss - MassDevice
CVRx stock touches 52-week low at $6.36 amid market challenges - Investing.com
Cantor Fitzgerald maintains CVRx stock Overweight rating - Investing.com
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
CVRx price target lowered to $14 from $19 at Lake Street - TipRanks
Assessing CVRx: Insights From 4 Financial Analysts - Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Canaccord cuts CVRx stock target to $18, maintains Buy rating By Investing.com - Investing.com India
Top Premarket Decliners - MarketScreener
Canaccord cuts CVRx stock target to $18, maintains Buy rating - Investing.com
CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
CVRx (CVRX) Stock Drops as Preliminary Q1 2025 Revenue Disappoin - GuruFocus
CVRx stock slides on preliminary revenue miss (CVRX:NASDAQ) - Seeking Alpha
CVRx Sees Q1 Higher Revenue YOY, Missing Consensus -- Shares Fall After Hours - MarketScreener
CVRx Reports Preliminary First Quarter 2025 Financial Results - The Manila Times
CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues - Stock Titan
(CVRX) Long Term Investment Analysis - news.stocktradersdaily.com
Bank of New York Mellon Corp Increases Stake in CVRx, Inc. (NASDAQ:CVRX) - Defense World
CVRx stock plunges 42% in wake of Q1 report, updated forecast - MSN
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Several Insiders Invested In CVRx Flagging Positive News - Yahoo
Cantor Fitzgerald maintains CVRx stock with $20 target By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains CVRx stock with $20 target - Investing.com
(CVRX) Trading Report - Stock Traders Daily
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For - Simply Wall St
Power Shift 25: Medtech firm's new CEO looks to 'build a world-class team'Minneapolis / St. Paul Business Journal - Minneapolis / St. Paul Business Journal
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Analyzing Co-Diagnostics (NASDAQ:CODX) and CVRx (NASDAQ:CVRX) - Defense World
CVRx, Inc. (NASDAQ:CVRX) Short Interest Down 9.8% in January - Defense World
CVRx, Inc. SEC 10-K Report - TradingView
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com UK
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim - GlobeNewswire
Cvrx, Inc. Announces New Real-World Evidence Demonstrating Significant Reductions in Healthcare Utility with Barostim - Marketscreener.com
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvrx Inc-Aktie (CVRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Option Exercise |
5.14 |
2,500 |
12,852 |
3,305 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Nov 19 '24 |
Sale |
13.58 |
1,430 |
19,417 |
1,875 |
0.85%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):